Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Eli Lilly and Company

35 indications, side-by-side phase, drug & LoA

$1,133

-26.95 (-2.32%)

A 94Pipeline Score Overvalued Pharma · Commercial
Market Cap
1002.95 B
EPS
27.82
P/E Ratio
38.34 $
Value Trade
2.87 B
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    19.80 B

  • R&D Expenses

    3.51 B

  • Operating CF

    5.33 B

  • Total Assets

    116.58 B

  • Total Liabilities

    116.58 B

  • Equity

    31.20 B

  • D/E Ratio

    12,345

5.76 %
Week
17.5 %
1 Month
4.02 %
3 Month
2.31 %
6 Month
432.5 %
5 Year
37,819.33 %
All Time
Cash Data
Profitable

  • Cash Position

    5.28 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Apr 30, 2026
Overview
Volume
2.44 M
52 Week Range
623.78 - 1,133.95
% held by Insiders
10.05 %
% held by Institutions
74.79 %
Enterprise Value
1041.04 B
Total Shares
944.82 M
Short %
1.15 %
Float Shares
851.28 M
Company Description
HQ: LILLY CORPORATE CTR, INDIANAPO...
Employees:50,000
https://www.lilly.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
Jaypirca (pirtobrutinib) relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Phase 3
—
Small Molecules
Hematologic System
Jaypirca (pirtobrutinib) relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Phase 3
—
Small Molecules
Hematologic System
Jaypirca (pirtobrutinib) relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Phase 3
—
Small Molecules
Hematologic System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A94
Pipeline Score
$287.8B
Pipeline Value
Overvalued
Valuation Signal
374
Drugs Scored
0.3x
rNPV / MCap
Top 100%
Large Pharma
(rank 1 of 905)
Percentile Rank
Eli Lilly and Company earns an A-grade pipeline score (94/100), with $287.8B risk-adjusted pipeline value, led by LY2189265 in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
LY2189265
Monoclonal antibody		Diabetes Mellitus, Type 2Phase 3NCT0140888867% $17.4B COMPLETED 8,059 - -Apr 1, 2012 -Oct 7, 2014
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Zepbound (tirzepatide)
obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea
Phase 2
2025-06-16
Zepbound (tirzepatide)
obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea
Phase 2
2025-06-16
Zepbound (tirzepatide)
obesity,overweight with weight-related medical conditions,moderate-to-severe obstructive sleep apnea
Phase 2
2025-06-16
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in LLY
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LLY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
LLY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
LLY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2027-03-19 0.00 0 - - - - - -
2027-03-19 0.00 0 - - - - - -
2027-03-19 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Eli Lilly and Company (LLY) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How LLY ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Obesity #1 of 33 PHASE 3 Retatrutide
AMGN NVO RYTM
$22.52B 0.95 LEADER
Type 2 Diabetes #1 of 33 PHASE 3 Retatrutide
AMGN NVO PFE
$25.4B 0.97 LEADER
Osteoarthritis #1 of 13 PHASE 3 Eloralintide
PCRX NVO BVS
$6.0B 0.97 LEADER
Atopic Dermatitis #1 of 25 PHASE 3 Baricitinib + corticosteroid
ABBV PFE SNY
$20.76B 0.92 LEADER
Type 1 Diabetes #1 of 19 PHASE 3 Tirzepatide
NVO SNY DXCM ·dev
 $3.5B 0.93 LEADER
Chronic Pain #1 of 16 PHASE 3 Retatrutide
BSX ·dev CELZ ZBH ·dev
 $91.35B 0.96 LEADER
Sleep Disorders #1 of 14 PHASE 3 Retatrutide
NVO AMGN INSP
$3.95B 0.96 LEADER
General Cardiovascular Diseases #1 of 16 PHASE 3 Retatrutide
UTHR EW ·dev ABT ·dev
—0.96 LEADER
Hypertension #1 of 16 PHASE 3 Orforglipron
ALNY MLYS UTHR
$9.41B 0.97 LEADER
Thyroid Cancer #1 of 12 PHASE 3 Selpercatinib + Cabozantinib + Vandetanib
NVS EXEL MRK
$4.2B 0.95 LEADER
Peripheral Artery Disease #1 of 17 PHASE 3 Orforglipron
REGN ABT ·dev MMSI
—0.95 LEADER
Substance Use Disorders #1 of 8 PHASE 3 LY3537031
ALT CMND HBIO
—0.95 LEADER
Dyslipidemia #1 of 9 PHASE 3 Lepodisiran
MRK NVS NAMS
$16.03B 0.86 LEADER
Urinary Disorders #1 of 4 PHASE 3 Orforglipron
INMD BDX ·dev ATLN
—0.98 LEADER
Psychiatric Disorders #1 of 3 PHASE 3 Donanemab + Dexamethasone
MASI HCSG
—0.93 LEADER
Neuropathic Pain #1 of 6 PHASE 2 LY3848575
DWTX SGMO UBX
$8.73B 0.93 LEADER
Hormonal Disorders #1 of 5 PHASE 3 Abemaciclib + Abiraterone + Prednisone or Prednisolone
AZN ABCL BMY
—0.91 LEADER
Addiction #1 of 1 PHASE 2 Brenipatide
—
 $1.5B 0.97 LEADER
Allergic Rhinitis #1 of 3 PHASE 3 LY3650150 + Standard therapy for INCS
PLRZ REGN
$16.1B 0.95 LEADER
Hearing Loss #1 of 2 PHASE 1 AAVAnc80-hOTOF via Akouos Delivery Device
COCH
$7.53B 0.88 LEADER
Lymphoma #2 of 69 PHASE 3 Pirtobrutinib + Idelalisib + Bendamustine + Rituximab
REGN MRK AZN
$8.52B 0.85 LEADER
Leukemia #2 of 64 PHASE 3 Pirtobrutinib + Idelalisib + Bendamustine + Rituximab
AMGN AZN MRK
$4.28B 0.84 LEADER
Rheumatoid Arthritis #2 of 28 PHASE 3 Baricitinib
ABBV BMY JNJ
$4.2B 0.95 LEADER
Chronic Kidney Disease #2 of 27 PHASE 3 Retatrutide
AZN NVO FMS
$96.33B 0.91 LEADER
Crohn's Disease #2 of 15 PHASE 3 Mirikizumab
SNY ABBV JNJ
$12.67B 0.87 LEADER
Alzheimer's Disease #2 of 24 PHASE 3 Donanemab + Dexamethasone
BMY BIIB ANVS
$6.49B 0.93 LEADER
General Hematological Disorders #2 of 4 PHASE 2 LY2784544
VRTX AZN AAPG
—0.97 CONTENDER
Uveitis #2 of 5 PHASE 3 Baricitinib + Adalimumab
ROIV ANIP REGN
$1.2B 0.85 CONTENDER
Ovarian Cancer #3 of 61 PHASE 3 Sofetabart Mipitecan + Paclitaxel + Topotecan + Gemcitabine + Pegylated liposomal doxorubicin + MIRV + Bevacizumab + Carboplatin
MRK AZN ABBV
$4.0B 0.87 LEADER
Ulcerative Colitis #3 of 17 PHASE 3 Mirikizumab
SNY JNJ ABBV
$6.5B 0.86 LEADER
Sarcoma #3 of 31 PHASE 2 Abemaciclib + Irinotecan + Temozolomide
NVS INTS PFE
$1.75B 0.9 CONTENDER
Cholangiocarcinoma #3 of 24 PHASE 2 Ramucirumab + Merestinib + Cisplatin + Gemcitabine
AZN JAZZ TNGX
$0.62B 0.92 CONTENDER
Atherosclerosis #3 of 15 PHASE 3 Lepodisiran
NVO NVS AMGN
—0.86 LEADER
Migraine #3 of 5 PHASE 3 Galcanezumab
ABBV PFE AMGN
$7.02B 0.96 CONTENDER
NASH / MASH #3 of 11 PHASE 3 Tirzepatide + Retatrutide
MDGL NVO REGN
$7.87B 0.93 CONTENDER
Skin Disorders #3 of 15 PHASE 3 Baricitinib
INCY SNY AMGN
—0.92 CONTENDER
Pediatric Conditions #3 of 8 PHASE 2 Ramucirumab + Cyclophosphamide + Vinorelbine + Gemcitabine + Docetaxel + Abemaciclib + Irinotecan + Temozolomide
BCRX CYTK SUPN
$28.2B 0.91 CONTENDER
Chronic Rhinosinusitis #3 of 4 PHASE 3 LY3650150 + Standard therapy for INCS
SNY AZN REGN
$3.11B 0.98 CONTENDER
Breast Cancer #4 of 94 PHASE 3 Abemaciclib + Standard Adjuvant Endocrine Therapy
MRK AZN GILD
$10.85B 0.9 LEADER
Alopecia #4 of 12 PHASE 3 Baricitinib
PFE MANE ABBV
$10.76B 0.92 CONTENDER
Non-Small Cell Lung Cancer #5 of 88 PHASE 3 Selpercatinib + Carboplatin + Cisplatin + Pemetrexed + Pembrolizumab
MRK AMGN AZN
$28.1B 0.91 LEADER
Prostate Cancer #5 of 53 PHASE 3 Abemaciclib + Abiraterone + Prednisone or Prednisolone
MRK AZN PFE
$25.12B 0.78 LEADER
Cervical Cancer #5 of 31 PHASE 1 LY4101174
AZN MRK PFE
$2.8B 0.94 CONTENDER
Bipolar Disorder #5 of 12 PHASE 2 Brenipatide
BMY ABBV ALKS
$10.5B 0.95 CONTENDER
Bladder Cancer #6 of 47 PHASE 3 Vepugratinib + EV + Pembrolizumab
AZN BMY JNJ
$0.33B 0.91 LEADER
Psoriasis #6 of 15 PHASE 3 Ixekizumab + Tirzepatide
JNJ BMY ABBV
$26.66B 0.97 CONTENDER
Psoriatic Arthritis #6 of 13 PHASE 3 Ixekizumab + Adalimumab
JNJ ABBV BMY
—0.88 CONTENDER
Schizophrenia #6 of 15 PHASE 2 Brenipatide
NBIX BMY ALKS
$2.5B 0.98 FOLLOWER
Brain Tumors #7 of 45 PHASE 2 Abemaciclib + Temozolomide
NVCR JAZZ DAWN
$3.55B 0.87 FOLLOWER
Esophageal Cancer #7 of 39 PHASE 2 Ramucirumab + Paclitaxel
MRK AZN ONC
$1.85B 0.9 CONTENDER
Neuropathy #7 of 20 PHASE 2 LY3848575
VRTX ARGX SNY
$8.0B 0.94 CONTENDER
Hidradenitis Suppurativa #7 of 13 PHASE 2 Eltrekibart
ABBV INCY NVS
$1.7B 0.95 FOLLOWER
Dyslipidemia / Hypercholesterolemia #7 of 14 PHASE 2 Solbinsiran
NVS ARWR MRK
—0.89 FOLLOWER
Parkinson's Disease #8 of 22 PHASE 1 LY3884961 + Methylprednisolone + Sirolimus
SUPN PRTA BHVN
$5.96B 0.93 FOLLOWER
Multiple Sclerosis #9 of 20 PHASE 2 LY3541860
SNY NVS BIIB
$31.92B 0.9 FOLLOWER
Lung Cancer #10 of 79 PHASE 3 Ramucirumab + Erlotinib + Gefitinib + Osimertinib
MRK GILD AMGN
$28.1B 0.91 CONTENDER
Endometrial Cancer #10 of 48 PHASE 1 LY3537982 + Pembrolizumab + Cetuximab + Pemetrexed + Cisplatin + Carboplatin
MRK AZN GILD
$31.09B 0.93 FOLLOWER
Major Depressive Disorder #10 of 31 PHASE 3 Brenipatide
CMPS NBIX JNJ
$12.0B 0.95 CONTENDER
Asthma #10 of 16 PHASE 2 Brenipatide
NVS TEVA GSK
$30.84B 0.95 FOLLOWER
Myeloproliferative Neoplasms #10 of 14 PHASE 1 LY3410738 + Venetoclax + Azacitidine
BMY ABBV NVS
—0.84 FOLLOWER
ALS #10 of 15 PHASE 1 89Zr-DFO-AP-101
AMLX BIIB IONS
$1.2B 0.8 FOLLOWER
Gastric Cancer #11 of 49 PHASE 2 Ramucirumab + Paclitaxel
AZN ONC JAZZ
$6.74B 0.84 FOLLOWER
Chronic Liver Disease #11 of 27 PHASE 1 Lepodisiran
GSK GILD MDGL
$19.9B 0.97 FOLLOWER
Pancreatic Cancer #12 of 73 PHASE 1 LY4101174
RVMD RCUS AZN
$3.7B 0.93 FOLLOWER
Thrombocytopenia #12 of 18 PHASE 1 Pirtobrutinib
NVS TAK ARGX
$1.85B 0.89 FOLLOWER
Colorectal Cancer #13 of 82 PHASE 2 LY2157299 + Capecitabine + Fluorouracil
ABBV BMY MRK
$7.68B 0.91 CONTENDER
Myelodysplastic Syndromes #14 of 33 PHASE 1 LY3410738 + Venetoclax + Azacitidine
BMY ABBV TAK
$2.5B 0.84 FOLLOWER
Systemic Lupus Erythematosus #15 of 32 PHASE 1 LY4298445
BIIB VTRS BMY
$2.78B 0.99 FOLLOWER
Rare Metabolic Disorders #17 of 30 PHASE 1 LY3884961 + Methylprednisolone + Sirolimus + Prednisone
AZN SNY TVTX
$21.15B 0.76 FOLLOWER
Multiple Myeloma #19 of 27 PHASE 1 LOXO-338 + Pirtobrutinib
JNJ ABBV BMY
$23.78B 0.92 FOLLOWER
Head and Neck Cancer #21 of 63 PHASE 1 LY4101174
AZN GSK MRK
$10.2B 0.95 FOLLOWER
Rare Genetic Disorders #47 of 61 PHASE 1 Selpercatinib
BMRN ASND NVS
—0.89 FOLLOWER